Short Interest in Replimune Group, Inc. (NASDAQ:REPL) Rises By 18.0%

Replimune Group, Inc. (NASDAQ:REPL) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totalling 7,160,000 shares, an increase of 18.0% from the September 30th total of 6,070,000 shares. Based on an average daily volume of 684,000 shares, the short-interest ratio is presently 10.5 days.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Replimune Group in a research note on Monday, September 16th. JPMorgan Chase & Co. upped their target price on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Finally, Roth Mkm initiated coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target on the stock. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $16.80.

Replimune Group Price Performance

NASDAQ:REPL traded down $0.03 during mid-day trading on Wednesday, hitting $12.25. The company’s stock had a trading volume of 137,733 shares, compared to its average volume of 1,066,059. The company has a market capitalization of $752.33 million, a price-to-earnings ratio of -3.79 and a beta of 1.21. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $15.02. The stock has a fifty day moving average of $11.04 and a 200-day moving average of $9.10.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.10. As a group, equities analysts forecast that Replimune Group will post -3.05 EPS for the current fiscal year.

Insider Buying and Selling

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the completion of the transaction, the chief financial officer now directly owns 101,057 shares of the company’s stock, valued at approximately $1,028,760.26. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 20.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

A number of hedge funds have recently made changes to their positions in REPL. Nisa Investment Advisors LLC grew its position in Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after acquiring an additional 4,946 shares during the last quarter. Point72 DIFC Ltd bought a new stake in Replimune Group during the 2nd quarter worth about $57,000. Diversified Trust Co acquired a new position in shares of Replimune Group during the first quarter worth approximately $94,000. Arizona State Retirement System bought a new stake in shares of Replimune Group during the second quarter valued at approximately $108,000. Finally, Quest Partners LLC increased its holdings in shares of Replimune Group by 30.4% in the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after purchasing an additional 3,150 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.